Pharmacokinetic-pharmacodynamic target attainment analysis of biapenem in adult patients: A dosing strategy

被引:22
|
作者
Ikawa, Kazuro [1 ]
Morikawa, Norifumi [1 ]
Ikeda, Kayo [1 ]
Ohge, Hiroki [2 ]
Sueda, Taijiro [2 ]
Suyama, Hidemichi [3 ]
Doi, Masao [4 ]
Kuwabara, Masao [4 ]
机构
[1] Hiroshima Univ, Grad Sch Biomed Sci, Dept Clin Pharmacotherapy, Minami Ku, Hiroshima 7348551, Japan
[2] Hiroshima Univ, Grad Sch Biomed Sci, Dept Surg, Hiroshima 7348551, Japan
[3] Hiroshima Prefectural Hosp, Crit Care Med Ctr, Hiroshima, Japan
[4] Hiroshima Prefectural Hosp, Dept Internal Med, Hiroshima, Japan
来源
CHEMOTHERAPY | 2008年 / 54卷 / 05期
关键词
biapenem; pharmacokinetics; pharmacodynamics; Monte Carlo simulation; dosing regimen;
D O I
10.1159/000152459
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: A pharmacokinetic-pharmacodynamic (PK-PD) target attainment analysis to build a dosing strategy for biapenem in adult patients has not been conducted. Methods: A total of 321 plasma concentration samples from 68 adult patients (1-6 samples per patient) were assayed biologically and chromatographically, and used for a population PK modeling and Monte Carlo simulation to assess the probability of attaining the PK-PD target (40% of the time above the minimum inhibitory concentration). Results: The population PK model was based on the standard two-compartment model, and creatinine clearance (Cl-cr) was the most significant covariate that affected the drug clearance. The Monte Carlo simulation demonstrated that the dosages up to 600 mg Q12H (0.5-h infusions) achieved a PK-PD target attainment probability of >= 90%, which varied with Cl-cr of the patient and susceptibility of the tested bacterium; however, higher dosage with prolonged infusion time (600 mg Q8H, 3 h infusion) was required for a high probability against Pseudomonas aeruginosa and Haemophilus influenzae isolates in the case of Cl-cr = 90 ml/min. Conclusion: These results provide guidance for constructing a PK-PD-based strategy for tailoring biapenem regimens in adult patients. Copyright (C) 2008 S. Karger AG, Basel.
引用
收藏
页码:386 / 394
页数:9
相关论文
共 50 条
  • [1] Pharmacokinetic-pharmacodynamic target attainment analysis of meropenem in Japanese adult patients
    Ikawa, Kazuro
    Morikawa, Norifumi
    Ohge, Hiroki
    Ikeda, Kayo
    Sueda, Taijiro
    Taniwaki, Masafumi
    Kurisu, Kaoru
    [J]. JOURNAL OF INFECTION AND CHEMOTHERAPY, 2010, 16 (01) : 25 - 32
  • [2] Pharmacokinetic-pharmacodynamic target attainment analysis of doripenem in infected patients
    Ikawa, Kazuro
    Morikawa, Norifumi
    Uehara, Shinya
    Monden, Koichi
    Yamada, Yoshiaki
    Honda, Nobuaki
    Kumon, Hiromi
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2009, 33 (03) : 276 - 279
  • [3] Population pharmacokinetic-pharmacodynamic target attainment analysis of sulbactam in patients with impaired renal function: Dosing considerations for Acinetobacter baumannii infections
    Yokoyama, Yuta
    Matsumoto, Kazuaki
    Ikawa, Kazuro
    Watanabe, Erika
    Morikawa, Norifumi
    Takeda, Yasuo
    [J]. JOURNAL OF INFECTION AND CHEMOTHERAPY, 2015, 21 (3-4) : 284 - 289
  • [4] Optimising ciprofloxacin dosing in intensive care patients based on pharmacodynamic target attainment through the use of population pharmacokinetic-pharmacodynamic analysis and Monte Carlo simulation
    Khachman, D.
    Conil, J.
    Georges, B.
    Saivin, S.
    Houin, G.
    Toutain, P.
    Laffont, C.
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2011, 25 : 2 - 2
  • [5] RATIONAL WARFARIN DOSING - A PHARMACOKINETIC-PHARMACODYNAMIC ANALYSIS
    HOLFORD, NHG
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1986, 39 (02) : 199 - 199
  • [6] Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints
    Bhavnani, S. M.
    Trang, M.
    Griffith, D. C.
    Lomovskaya, O.
    Hammel, J. P.
    Loutit, J. S.
    Cammarata, S. K.
    Dudley, M. N.
    Ambrose, P. G.
    Rubino, C. M.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2022, 66 (12)
  • [7] Assessment of micafungin regimens by pharmacokinetic-pharmacodynamic analysis: a dosing strategy for Aspergillus infections
    Ikawa, Kazuro
    Nomura, Kenichi
    Morikawa, Norifumi
    Ikeda, Kayo
    Taniwaki, Masafumi
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 64 (04) : 840 - 844
  • [8] Assessment of pharmacokinetic-pharmacodynamic target attainment of gemifloxacin against Streptococcus pneumoniae
    Owens, RC
    Bhavnani, SM
    Ambrose, PG
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2005, 51 (01) : 45 - 49
  • [9] Population Pharmacokinetic-Pharmacodynamic Target Attainment Analysis of Flomoxef in the Serum and Liver Tissue of Patients Undergoing Hepatic Resection
    Komatsu, Toshiaki
    Tsumuraya, Satomi
    Takayama, Yoko
    Kaizu, Takashi
    Okamoto, Mikiko
    Tajima, Hiroshi
    Nishizawa, Nobuyuki
    Kubo, Hidefumi
    Kumamoto, Yusuke
    Okamoto, Hirotsugu
    Hanaki, Hideaki
    Atsuda, Koichiro
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2022, 66 (04)
  • [10] Population Pharmacokinetic-Pharmacodynamic Target Attainment Analysis of Imipenem Plasma and Urine Data in Neonates and Children
    Yoshizawa, Kenichi
    Ikawa, Kazuro
    Ikeda, Kayo
    Ohge, Hiroki
    Morikawa, Norifumi
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2013, 32 (11) : 1208 - 1216